ABOUT
We are building transformative cell & gene therapy ventures
TEAM
We are experienced cell therapy developers, innovators, and company builders
Stefan Wildt, PhD
CEO, CO-FOUNDER
Takeda R&D CTO, CGTx development, Biopharma executive leadership
Nebojsa Milovic, PhD
CTO, CO-FOUNDER
CGTx development, manufacturing and tech innovation
Ulrik Nielsen, PhD
EXECUTIVE CHAIR,
CO-FOUNDER
Multi-time founder, Merrimack, Torque, Notch, Tidal
Iulia Diaconu, PhD
PRECLINICAL DEVELOPMENT
CSO Unikum Therapeutics, IND submissions, academia and industry partnerships
Johannes Fruehauf, MD PhD PRESIDENT, CO-FOUNDER
Venture capital, biotech entrepreneur
Adel Nada, MD, MS
VENTURE PARTNER
Multi-time founder, CEO, CMO, Clinical Development
Nandhu Mohan Sobhana, PhD
CELL ENGINEERING & PRODUCT DESIGN
R&D to IND and clinical success, various CGTx platforms, novel engineering
Arun Ramamurthy, MS, MBA
PRODUCT DEVELOPMENT & MANUFACTURING
CMC, clinical and commercial GMP manufacturing, partnerships and operations
Jennifer Camacho, JD LEGAL & IP
legal and IP support for biotech startups
Jim Magee,
FINANCE & ACCOUNTING
Infrastructure design & implementation, finance, accounting & HR
TRACK RECORD
Decades of leading the Cell & Gene frontline
OUR INVESTORS
Empowering Innovation Together
PIPELINE
Volnay Ventures and Pipeline Overview
We are biotech venture builders and drug developers with decades of experience in cell & gene therapies. We have created a novel model to unlock innovation in this transformative space, delivering life-saving treatments and making them accessible to patients worldwide.
As a highly collaborative hub-and-spoke company, we center our expertise and capabilities on product development and technology innovation. We scout for scientific breakthroughs, and we form ventures around those with disruptive, high-value potential.
We support our ventures by providing initial capital, interim leadership, and expert execution. By accelerating and de-risking progress towards preclinical proof-of-concept and clinical validation, we ensure quality, rapid value inflections and commercial viability.
Our efficient operating structure aggregates capital and deploys expertise and resources across multiple ventures. By mitigating clinical risks and validating commercial potential, we create significant value for investors and patients.
BUILDING TEAMS & COMPANIES
Built and led high-performing CGTx teams and startups
C suite Pharma leadership of global 1000+ people teams
Established in international markets (US, JP, EU)
ESTABLISHING CAPABILITIES
Successful academic partnerships & strong network of innovators
Built & led CMC labs & GMP operations
Enabled partnerships with CDMOs and suppliers
Created and employed lab automation and industry 4.0 tech
DELIVERING PRODUCTS & TECH
APPROVED PRODUCTS
Kymriah®, Abecma®, Alofisel®
INDs
CARTs, CAR-NKs, iPSCs, γδT, HSCs, MSCs
MFRG. AUTOMATION
Automated cell processing, smart bioreactors, gene delivery, fill & finish
EXITS
Tidal Therapeutics, GlycoFi
TEAM
Board of Directors
Stefan Wildt, PhD
CEO
Ulrik Nielsen, PhD
EXECUTIVE CHAIR
Johannes Fruehauf, MD PhD
PRESIDENT
Manu Nair, LL.M, MBA
MAYO CLINIC
Cassidy Blundell, PhD
MISSION BIOCAPITAL
Gali Baler, PhD
CU INNOVATIONS
Board observer